Figure 3 | Scientific Reports

Figure 3

From: Combined serum albumin, fecal immunochemical test, and leucine-rich alpha-2 glycoprotein levels for predicting prognosis in remitting patients with ulcerative colitis

Figure 3

(a) Cumulative non-recurrence rates in patients with serum albumin ≤ 4.4 mg/mL and patients with albumin > 4.4 mg/mL (P = 0.0034; log-rank test). (b) Cumulative non-recurrence rates in patients with FIT ≤ 30 ng/mL and patients with FIT > 30 ng/mL (P = 0.0100; log-rank test). (c) Cumulative non-recurrence rates in patients with (1) FIT ≤ 30 ng/mL and Alb > 4.4 g/dL, (2) FIT ≤ 30 ng/mL and Alb ≤ 4.4 g/dL, (3) FIT > 30 ng/mL and Alb > 4.4 g/dL, and (4) FIT > 30 ng/mL and Alb ≤ 4.4 g/dL. Patients the patients with FIT > 30 ng/mL and Alb ≤ 4.4 g/dL have higher relapse rates than those with FIT ≤ 30 ng/mL and Alb ≤ 4.4 g/dL (P = 0.0041; log-rank test with Bonferroni correction) and those with FIT ≤ 30 ng/mL and Alb > 4.4 g/dL (P = 0.0001; log-rank test with Bonferroni correction). *P < 0.05, **P < 0.01, ***P < 0.0083. LRG leucine-rich alpha-2-glycoprotein, FIT fecal immunochemical test, Alb albumin.

Back to article page